



MaxCyte Signs Clinical and Commercial License with Sana Biotechnology

August 9, 2021

Agreement represents MaxCyte's 14th strategic platform license (SPL)

Sana will use MaxCyte's Flow Electroporation® technology and ExPERT™ platform in conjunction with the development of its hypoimmune cell therapy programs

GAITHERSBURG, Md., Aug. 9, 2021 /PRNewswire/ -- MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines.

Under the terms of the agreement, Sana Biotechnology obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return MaxCyte is entitled to receive platform licensing fees and program-related milestone payments.

Doug Doerfler, President and CEO of MaxCyte, said: "We are delighted to support Sana's *ex vivo* cell therapy programs and recognize the potential of the company's novel hypoimmune cell platform to advance treatments for serious diseases. This agreement represents an important achievement for MaxCyte as we continue to expand the use of our next-generation technology platform to support the development of innovative treatments."

MaxCyte's ExPERT instrument portfolio represents the next generation of leading, clinically-validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies — including 20 of the top 25 pharmaceutical companies based on 2020 global revenue — to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

MaxCyte Contacts:

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer

+1 301-944-1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black / Duncan Monteith / Matthew O'Dowd

+44 (0)20 7260 1000

Joint Corporate Broker

Stifel Nicolaus Europe Limited

Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams

+44 (0)20 7710 7600

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott
Chris Welsh

+44 (0)203 709 5700

maxcyte@consilium-comms.com

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com

US Media Relations
Jamie Lacey-Moreira
PressComm PR, LLC

+1 410-299-3310
jamielacey@presscommpr.com

 View original content: <https://www.prnewswire.com/news-releases/maxcyte-signs-clinical-and-commercial-license-with-sana-biotechnology-301350765.html>

SOURCE Maxcyte, Inc.